Navigation Links
Light and nanoprobes detect early signs of infection
Date:6/20/2013

DURHAM, N.C. -- Duke University biomedical engineers and genome researchers have developed a proof-of-principle approach using light to detect infections before patients show symptoms.

The approach was demonstrated in human samples, and researchers are now developing the technique for placement on a chip, which could provide fast, simple and reliable information about a patient. A diagnostic device based on this chip also could be made portable.

The researchers developed a silver-based nanoparticle that homes in on a specific molecular marker that spills into the bloodstream at the first stages of an infection. When light is aimed at the sample, the nanoparticle attached to a molecular marker will reflect a distinct optical fingerprint.

"We have demonstrated for the first time that the use of these nanoprobes can detect specific genetic materials taken from human samples," said Tuan Vo-Dinh, the R. Eugene and Susie E. Goodson Distinguished Professor of Biomedical Engineering at Duke' Pratt School of Engineering and director of The Fitzpatrick Institute for Photonics at Duke. He is also a professor of chemistry.

The results of the Duke experiments appear online in the journal Analytica Chimica Acta. Hsin-Neng Wang, a post-doctoral fellow in Vo-Dinh's laboratory, was the first author of the paper.

In this interdisciplinary project, the Vo-Dinh team collaborated closely with scientists at Duke's Institute for Genome Sciences & Policy (IGSP) who have developed a method of measuring the host's response to infection through RNA profiling.

The research is supported by the National Institutes of Health, the Defense Advanced Projects Agency, the Department of Defense and the Wallace H. Coulter Foundation.

In the Duke experiments, the nanoprobes are used in conjunction with a phenomenon first described in the 1970s known as surface-enhanced Raman scattering (SERS). When light, usually from a laser, is shined on a sample, the target molecule vibrates and scatters back in its own unique light, often referred to as the Raman scatter. However, this Raman response is extremely weak.

"When the target molecule is coupled with a metal nanoparticle or nanostructure, the Raman response is greatly enhanced by the SERS effect often by more than a million times," said Vo-Dinh, who has been studying the potential applications of SERS for decades.

"This important proof-of-concept study now paves the way for the development of devices that measure multiple genome-derived markers that will assist with more accurate and rapid diagnosis of infectious disease at the point of care," said Geoffrey Ginsburg, director of genomic medicine at the IGSP, executive director of the Center for Personalized Medicine at Duke Medicine, and a professor of medicine and pathology.

"This would guide care decisions that will lead to more effective treatment and improved outcomes of antimicrobial therapy," Ginsburg said. "Point-of-care diagnostics holds great promise to accelerate precision medicine and, more importantly, help patients in limited-resource settings gain access to molecular testing."


'/>"/>

Contact: Richard Merritt
Richard.merritt@duke.edu
919-660-8414
Duke University
Source:Eurekalert

Related biology news :

1. New study shines light on barriers to diabetes care in NYC Bangladeshi community
2. EPA to highlight innovative ways to detect and respond to biological threats
3. Ancient whale species sheds new light on its modern relatives
4. Linking and lightening: New partnership connects and reveals dark data
5. AGU journal highlights for March 29, 2012
6. AGU journal highlights for April 16, 2012
7. Folding light: Wrinkles and twists boost power from solar panels
8. Light weights are just as good for building muscle, getting stronger, researchers find
9. Creating energy from light and air - new research on biofuel cells
10. IBNs Droplet Array sheds light on drug-resistant cancer stem cells
11. The music of the (hemi)spheres sheds new light on schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: